Quick Links
Abbott Labs Q1 2025: EPS Beat and Margin Expansion Drive 5% Surge, But Revenue Miss and FX Headwinds Cloud Outlook
Data Snapshot
Key Takeaways
- •Abbott's adjusted EPS of $1.09 beat consensus by ~1.9%, with adjusted gross margin expanding 140 bps to 57.1% — demonstrating durable pricing power.
- •Medical Devices organic growth of ~13%, led by ~20% Diabetes Care growth, is the core earnings driver and raises the competitive bar for medtech peers.
- •Revenue of $10.358B slightly missed the $10.4B forecast, and COVID-19 testing revenue collapsed 59% YoY to $84M — structural headwinds remain in Diagnostics.
- •Abbott reaffirmed full-year 2025 guidance despite tariff risks; claims of a FY2026 profit outlook cut are unverified in official sources.
- •A 2.8% FX headwind in Q1 highlights USD strength as an ongoing earnings governor for internationally exposed healthcare names.
Abbott Laboratories (ABT) reported Q1 2025 results on April 16, 2025, delivering a mixed-but-broadly-positive quarter. According to Abbott's official press release, adjusted EPS came in at $1.09 versu
Event Analysis
Abbott Laboratories (ABT) reported Q1 2025 results on April 16, 2025, delivering a mixed-but-broadly-positive quarter. According to Abbott's official press release, adjusted EPS came in at $1.09 versus the $1.07 consensus estimate — an 11% year-over-year increase — while revenue of $10.358 billion marginally missed forecasts of $10.4 billion. The headline that ABT "lowered FY26 adjusted profit outlook" appears inconsistent with the verified facts: the company actually reaffirmed its full-year 2025 guidance despite tariff headwinds, and no confirmed FY2026 downgrade is captured in available sources.
The standout story is Medical Devices, which posted roughly 13% organic growth, led by Diabetes Care at approximately 20% organic growth (27% in the U.S.). This signals Abbott's Boston Scientific and broader medtech peer group faces heightened competitive benchmarking. Adjusted gross margin expanded 140 basis points to 57.1%, and adjusted operating margin reached 21.0% — evidence of meaningful pricing power even in an inflationary environment. Diagnostics was the weak link, with COVID-19 testing revenue falling to $84 million from $204 million in Q1 2024, and China's volume-based procurement programs adding further drag.
FX remains a structural headwind: Abbott reported a 2.8% unfavorable year-over-year currency impact in Q1, with roughly 1% expected for the full year. For a company generating significant international revenue, USD strength is a persistent earnings governor that traders should track alongside the 2026 Forex Market Outlook.
What This Means for Traders
ABT's post-earnings reaction — a 5.17% surge per available data — reflects the market rewarding margin expansion and medical device momentum over the modest revenue miss. However, at the current live price of $101.53 (24h range: $100.66–$102.44), the stock is trading well below the 52-week high of $141.23 cited in research data, suggesting either significant post-announcement retracement or a data discrepancy traders should verify before positioning. Sentiment leans neutral-to-mildly bullish near-term, contingent on broader S&P 500 Index risk appetite.
For sector rotation, the outperformance in Medical Devices and Diabetes Care is a constructive signal for the State Street Health Care Select Sector SPDR ETF, while cross-sector peers like Johnson & Johnson and Becton, Dickinson and Company may face relative valuation pressure. The Diagnostics softness tied to China procurement is worth watching as a leading indicator of emerging market demand normalization — a theme with broader macro implications for multinational healthcare names. Volatility should normalize post-earnings absent fresh macro catalysts, though tariff policy developments remain a tail risk for guidance trajectories.
Trade Abbott Laboratories on CoinUnited.io
Trade ABT with up to 1000xx leverage → | Create Free Account
Frequently Asked Questions
Yes — Abbott reported adjusted EPS of $1.09, beating the $1.07 consensus estimate, though revenue of $10.358B slightly missed forecasts of $10.4B.
Continue Exploring
Disclaimer: This brief is for educational purposes only and is not investment advice.